Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome.

Milan PatelOmeed PartoviKatja KarrentoZhuping GaracchiGokulakrishnan BalasubramanianVenkatesan T

Published in: Neurogastroenterology and motility (2023)

A subset of patients with CVS have dysfunctional alleles of CYP2C19 and CYP2D6. Larger prospective studies to evaluate the clinical impact of pharmacogenomic testing in CVS are needed. This has the potential to optimize clinical management, predict ADRs and allow for personalized therapy.

Keyphrases

clinical decision support
case report
stem cells
risk assessment
chemotherapy induced
climate change
smoking cessation
bone marrow
replacement therapy